文献速递骨软组织肉瘤与黑色素瘤

儿科战略论坛:骨肉瘤多靶点激酶抑制剂药物研发——ACCELERATE与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
PubMed 文献 · Eur J Cancer · 2022-07-18

第八届儿科战略论坛聚焦骨肉瘤与尤文肉瘤的多靶点激酶抑制剂(mTKIs)研发。尽管已有临床与研究使用,mTKIs在骨肿瘤患者中的疗效尚未被明确证实;正在规划或进行的随机研究将提供数据。论坛强调预测性生物标志物与肿瘤生物学理解、生物样本共享及学术-产业联合体建设至关重要。

要点

  • mTKIs在骨肿瘤患者中的疗效尚未被明确证实。
  • 正在规划或进行的随机研究将提供一线与复发 settings 的数据。
  • 需共享生物样本并建立学术-产业联合体以评估mTKIs的生物学效应。

核心结论

  • mTKIs在骨肿瘤患者中的疗效尚未被明确证实,正在规划或进行的随机研究将推动该类药物进一步发展。
  • 加深对相关预测性生物标志物和肿瘤生物学的理解对该类药物开发至关重要。

研究设计与样本

  • 第八届儿科战略论坛,聚焦骨肉瘤与尤文肉瘤的多靶点激酶抑制剂(mTKIs)药物研发。

主要发现

  • 迄今经验普遍表明,mTKIs单药及与化疗或其他靶向治疗联合的安全性特征与成人一致,毒性可管理。
  • mTKIs在骨肿瘤患者中的疗效尚未被明确证实。
  • 正在规划或进行的随机研究将提供一线和复发 settings 的数据。

临床怎么用

  • 应共享用于转化研究和生物标志物开发的生物样本,并建立学术-产业联合体。
  • 临床试验设计应具备充分的科学依据以支持监管和支付方的要求。
  • 学术、产业、监管和患者倡导者之间的早期对话至关重要。
  • 应评估联合策略的可行性,并在同一方案中开展随机试验以加速药物开发。
  • 临床试验和开发应尽可能纳入儿童、青少年和40岁以下的成人。

局限性

  • mTKIs在骨肿瘤患者中的疗效尚未被明确证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The eighth Paediatric Strategy Forum focused on multi-targeted kinase inhibitors (mTKIs) in osteosarcoma and Ewing sarcoma. The development of curative, innovative products in these tumours is a high priority and addresses unmet needs in children, adolescents and adults. Despite clinical and investigational use of mTKIs, efficacy in patients with bone tumours has not been definitively demonstrated. Randomised studies, currently being planned or in progress, in front-line and relapse settings will inform the further development of this class of product. It is crucial that these are rapidly initiated to generate robust data to support international collaborative efforts. The experience to date has generally indicated that the safety profile of mTKIs as monotherapy, and in combination with chemotherapy or other targeted therapy, is consistent with that of adults and that toxicity is manageable. Increasing understanding of relevant predictive biomarkers and tumour biology is absolutely critical to further develop this class of products. Biospecimen samples for correlative studies and biomarker development should be shared, and a joint academic-industry consortium created. This would result in an integrated collection of serial tumour tissues and a systematic retrospective and prospective analyses of these samples to ensure robust assessment of biologic effect of mTKIs. To support access for children to benefit from these novel therapies, clinical trials should be designed with sufficient scientific rationale to support regulatory and payer requirements. To achieve this, early dialogue between academia, industry, regulators, and patient advocates is essential. Evaluating feasibility of combination strategies and then undertaking a randomised trial in the same protocol accelerates drug development. Where possible, clinical trials and development should include children, adolescents, and adults less than 40 years. To respond to emerging science, in approximately 12 months, a multi-stakeholder group will meet and review available data to determine future directions and priorities.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pearson AD, Gaspar N, Janeway K, et al. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022. PMID: 35863108. doi:10.1016/j.ejca.2022.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。